Share ownership Disc Medicine, Inc.

IRON

US2546041011

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2026-03-06 pm EST			5-day change	1st Jan Change
61.18 ^USD	+1.39%		-8.17%	-22.96%

Feb. 27	Disc Medicine's board approves restructuring plan	RE
Feb. 26	Disc Medicine, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI

Share class: Disc Medicine, Inc.

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	34,281,336	25,358,790 ( 73.97 %)	0	73.97 %

Major shareholders: Disc Medicine, Inc.

Name	Equities	%	Valuation
Fidelity Management & Research Co. LLC 14.44 %	5,450,222	14.44 %	421 M $
Access Industries, Inc. (New York) 7.455 %	2,814,379	7.455 %	218 M $
BlackRock Advisors LLC 5.632 %	2,126,220	5.632 %	164 M $
RA Capital Management LP 5.235 %	1,976,132	5.235 %	153 M $
Vanguard Fiduciary Trust Co. 4.683 %	1,767,680	4.683 %	137 M $
T. Rowe Price International Ltd. 4.498 %	1,698,005	4.498 %	131 M $
JPMorgan Investment Management, Inc. 4.188 %	1,581,127	4.188 %	122 M $
Wellington Trust Co., NA 4.022 %	1,518,274	4.022 %	117 M $
Atlas Venture Life Science Advisors LLC 4.01 %	1,513,875	4.01 %	117 M $
Frazier Life Sciences Management LP 3.338 %	1,260,000	3.338 %	97 M $
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Institutional	105.35%
Other	5.03%
State Street Corp.	3.15%
Individuals	2.25%
Manulife Financial Corp.	0.14%
Schweizerische Nationalbank	0.13%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	102.5%
United Kingdom	5.74%
Individuals	2.25%
Germany	1.56%
Switzerland	1.17%
Luxembourg	0.95%
Canada	0.58%
Australia	0.54%
Ireland	0.25%
Norway	0.24%
Sweden	0.13%
Cayman Islands	0.06%
Hong Kong	0.03%
Spain	0.02%
China	0.02%
Taiwan	0.01%

Based on 1000 largest holdings

Disc Medicine, Inc. is a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. The Company's pipeline includes bitopertin for the treatment of erythropoietic porphyrias (Eps) including erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF), and anemia of chronic kidney disease (CKD), and DISC-3405 (formerly MWTX-003) for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, its preclinical programs also include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Bitopertin is the lead product candidate in the Company's heme biosynthesis modulation portfolio. It is developing DISC-3405, a monoclonal antibody against Transmembrane Serine Protease 6 that it licensed from Mabwell Therapeutics, Inc.

Employees

155

Sector

Biotechnology & Medical Research

More about the company